Novel Agents for the Management of Endocrine Resistant Breast Cancer.

ABSTRACT:

Purpose of review

Most women with hormone receptor (HR)-positive, HER2-negative (HR+/HER2-) breast cancer will ultimately develop endocrine-resistant disease, either primary or acquired. This review will discuss the proposed mechanisms underlying endocrine resistance and key advances in the treatment of endocrine-resistant breast cancer.

Recent findings

Estrogen receptor 1 mutations (ESR1) occur in the majority of patients with HR+/HER2- metastatic breast cancer after prolonged exposure to aromatase inhibitors. Data from the SoFEA trial showed that patients had improved progression-free survival (PFS) after taking fulvestrant compared with exemestane. Fulvestrant is currently the only selective estrogen receptor degrader (SERD) available and development of oral novel

SUBMITTER: Reid-Lawrence S 

PROVIDER: S-EPMC8210781 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature